Analysts Set Bristol-Myers Squibb (NYSE:BMY) PT at $55.64

Shares of Bristol-Myers Squibb (NYSE:BMY) have received an average recommendation of “Hold” from the twenty-one ratings firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation, four have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $56.27.

A number of equities analysts have recently issued reports on the company. Barclays upped their price target on Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a research report on Monday, October 7th. Wolfe Research began coverage on Bristol-Myers Squibb in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. UBS Group raised their price target on Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, October 9th. Sanford C. Bernstein assumed coverage on Bristol-Myers Squibb in a research note on Thursday, October 17th. They set a “market perform” rating and a $56.00 price target on the stock. Finally, TD Cowen increased their price objective on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research report on Monday, October 7th.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now owns 11,760 shares in the company, valued at approximately $654,091.20. This represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Samit Hirawat acquired 1,830 shares of the company’s stock in a transaction on Friday, November 1st. The stock was acquired at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the acquisition, the executive vice president now owns 62,109 shares of the company’s stock, valued at $3,395,499.03. This trade represents a 3.04 % increase in their position. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Lantz Financial LLC lifted its stake in Bristol-Myers Squibb by 17.4% in the 2nd quarter. Lantz Financial LLC now owns 11,799 shares of the biopharmaceutical company’s stock valued at $490,000 after buying an additional 1,747 shares in the last quarter. Caprock Group LLC boosted its stake in shares of Bristol-Myers Squibb by 56.0% in the second quarter. Caprock Group LLC now owns 44,767 shares of the biopharmaceutical company’s stock worth $1,859,000 after acquiring an additional 16,069 shares during the last quarter. Quest Partners LLC increased its position in shares of Bristol-Myers Squibb by 29,957.4% during the second quarter. Quest Partners LLC now owns 40,878 shares of the biopharmaceutical company’s stock worth $1,698,000 after purchasing an additional 40,742 shares in the last quarter. First Foundation Advisors raised its stake in Bristol-Myers Squibb by 73.0% in the 2nd quarter. First Foundation Advisors now owns 5,656 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 2,386 shares during the last quarter. Finally, Wedbush Securities Inc. lifted its holdings in Bristol-Myers Squibb by 2.4% in the 2nd quarter. Wedbush Securities Inc. now owns 60,114 shares of the biopharmaceutical company’s stock valued at $2,497,000 after purchasing an additional 1,424 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Down 1.7 %

BMY opened at $55.84 on Wednesday. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The firm has a market cap of $113.25 billion, a price-to-earnings ratio of -15.55, a PEG ratio of 15.20 and a beta of 0.45. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.08. The stock has a fifty day moving average price of $57.44 and a 200-day moving average price of $51.56.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The business had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.26 billion. During the same period in the prior year, the firm posted $2.00 earnings per share. The company’s quarterly revenue was up 8.4% on a year-over-year basis. As a group, equities research analysts anticipate that Bristol-Myers Squibb will post 0.93 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be given a dividend of $0.62 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a yield of 4.44%. The ex-dividend date of this dividend is Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -69.08%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.